Literature DB >> 25370283

Treatment of bipolar depression.

Michael Berk1, Lesley Berk2, Christopher G Davey3, Steven Moylan2, Francesco Giorlando4, Ajeet B Singh2, Harish Kalra2, Seetal Dodd2, Gin S Malhi5.   

Abstract

Depression is usually the predominant phase in bipolar disorder, causes the most psychosocial disability, and carries significant risk of suicide. The management of bipolar depression is relatively under-studied and poses significant challenges for clinicians. There is substantial dissent regarding optimal pharmacotherapy for bipolar depression, particularly around the role of antidepressants. Individual and combination pharmacotherapy should be integrated into a personalised psychosocial and lifestyle package of interventions that considers the person's clinical profile and preferences. The relative lack of evidence relating to optimal strategies, especially when bipolar depression occurs with common comorbidities, poses challenges and requires further research. A flexible approach and evidence-based combinations of treatments can provide effective strategies for improving quality of life and reducing morbidity and mortality.

Entities:  

Mesh:

Year:  2013        PMID: 25370283     DOI: 10.5694/mja12.10611

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  Memory performance predicts response to psychotherapy for depression in bipolar disorder: A pilot randomized controlled trial with exploratory functional magnetic resonance imaging.

Authors:  Thilo Deckersbach; Amy T Peters; Conor Shea; Aishwarya Gosai; Jonathan P Stange; Andrew D Peckham; Kristen K Ellard; Michael W Otto; Scott L Rauch; Darin D Dougherty; Andrew A Nierenberg
Journal:  J Affect Disord       Date:  2017-12-27       Impact factor: 4.839

2.  Influence of adjuvant Coenzyme Q10 on inflammatory and oxidative stress biomarkers in patients with bipolar disorders during the depressive episode.

Authors:  Leila Jahangard; Fatemeh Yasrebifar; Mohammad Haghighi; Akram Ranjbar; Maryam Mehrpooya
Journal:  Mol Biol Rep       Date:  2019-07-25       Impact factor: 2.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.